Clinical trials: Bone
Osteogenesis Imperfecta (OI)
Open-label Extension of Study 20130173 of Denosumab in Children and Young Adults With Osteogenesis Imperfecta
To evaluate long-term safety of denosumab in children/young adults with pediatric osteogenesis imperfecta (OI) who completed the prior study 20130173 (NCT02352753).
- Trial name
- NCT03638128
- Testing
- Denosumab, Alternative osteoporosis medications
- Where
- 22 sites in United States, Australia and 10 more
- Volunteers
- 75 people
- Sponsor
- Amgen
Gastric Adenocarcinoma
Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma
The purpose of this study was to evaluate the efficacy of derazantinib monotherapy or derazantinib in combination with paclitaxel and ramucirumab in patients with gastric adenocarcinoma (GAC) i.e.
- Trial name
- FIDES-03 (NCT04604132)
- Testing
- Derazantinib, Derazantinib-paclitaxel-ramucirumab combination
- Where
- 81 sites in United States, Argentina and 13 more
- Volunteers
- 47 people
- Sponsor
- Basilea Pharmaceutica
Ankylosing Spondylitis
A Multicentre Study to Evaluate the Efficacy and Safety of ENIA11 in Patients With Ankylosing Spondylitis
This is a multi-center, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of ENIA11 in patients with ankylosing spondylitis.
- Trial name
- NCT02685904
- Testing
- ENIA11
- Where
- 6 sites in Taiwan
- Volunteers
- 10 people
- Sponsor
- Mycenax Biotech Inc.
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis
A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis
The purpose of this study is to assess the real-world safety of fedratinib for the treatment of adult participants with primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), or post essential…
- Conditions
- Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Trial name
- NCT06073847
- Testing
- Fedratinib
- Where
- 3 sites in South Korea
- Volunteers
- 137 people
- Sponsor
- Bristol-Myers Squibb
Hip Injuries, Fractures, Hip
Mitigation of Major Hip Injury Due to Fall With a Smart Belt
Multi-center, comparative, non-significant risk adaptive study with retrospective controls. After providing informed consent and being screened for eligibility, intervention subjects will be prescribed and provided an…
- Conditions
- Hip Injuries, Fractures, Hip, Fall Injury, Fall Risk
- Trial name
- NCT05245097
- Testing
- Tango Belt, Standard of Care (SOC)
- Where
- 10 sites in United States
- Volunteers
- 471 people
- Sponsor
- ActiveProtective Technologies, Inc
Achondroplasia
An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia
The intent and design of this Phase 3 study is to assess BMN 111 as a therapeutic option for the treatment of children with Achondroplasia
- Trial name
- NCT03424018
- Testing
- BMN 111
- Where
- 24 sites in United States, Australia and 5 more
- Volunteers
- 119 people
- Sponsor
- BioMarin Pharmaceutical
Gastro-enteropancreatic Neuroendocrine Tumor, Acromegaly
A Study to Understand Participant's Experiences in Gastro-enteropancreatic Neuroendocrine Tumors (GEP-NETs) and Acromegaly
Participants of this study are adults with GEP-NETs and/or acromegaly who were using the Ipsen lanreotide syringe and have transitioned in the last 6 months to the Pharmathen lanreotide syringe, having received at least two…
- Trial name
- BackSOM (NCT06253897)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Ipsen
Arthritis, Psoriatic
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
This is a study to confirm the clinical efficacy and safety of sonelokimab compared with placebo in the treatment of adults with active psoriatic arthritis who have had a previous inadequate response or intolerance to anti-tumor…
- Trial name
- IZAR-2 (NCT06641089)
- Testing
- Sonelokimab, Risankizumab
- Where
- 143 sites in United States, Bulgaria and 9 more
- Volunteers
- 600 people
- Sponsor
- MoonLake Immunotherapeutics AG
Degenerative Disc Disease, Herniated Disc
Bone Graft Materials Observational Registry
A multi-center, prospective, observational patient registry to collect information on the clinical outcomes and "real world" use of approved and commercially available bone graft substitutes, autograft and allograft.
- Conditions
- Degenerative Disc Disease, Herniated Disc, Spinal Stenosis, Spondylolithesis
- Trial name
- APPROACH-001 (NCT00974623)
- Testing
- Bone graft substitute, autograft or allograft
- Where
- 14 sites in United States, Hungary and 1 more
- Volunteers
- 329 people
- Sponsor
- Baxter Healthcare Corporation
Critical Limb Ischemia, Peripheral Artery Disease
Tolerability and Efficacy of Intravenous Infusion of Autologous MSC_Apceth for the Treatment of Critical Limb Ischemia
MSC_Apceth are GMP-manufactured, autologous ex-vivo expanded non-hemapoietic bone-marrow derived stem cells for the treatment of Critical Limb Ischemia
- Trial name
- NCT01351610
- Testing
- PTA + Infusion of MSC_Apceth, PTA
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- Apceth GmbH & Co. KG
Arthritis, Psoriatic
A Study of Guselkumab in Participants With Psoriatic Arthritis (PsA) in a Real-World Setting
The purpose of this study is to assess how well guselkumab works in improving symptoms of psoriatic arthritis (an inflammatory disease that affects the joints in participants with psoriasis, a skin condition that causes red…
- Trial name
- GURU (NCT07220824)
- Where
- 21 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Janssen Research & Development, LLC
Chronic Phase Chronic Myelogenous Leukemia, Accelerated Phase Chronic Myelogenous Leukemia
CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey
A multicenter, prospective cohort study of the mutation status of patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who are being treated with first or…
- Conditions
- Chronic Phase Chronic Myelogenous Leukemia, Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
- Trial name
- NCT03647215
- Where
- 33 sites in Ireland, United Kingdom
- Volunteers
- 427 people
- Sponsor
- Incyte Biosciences UK
Osteoporosis
A Study to Test the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis
The purpose of the study is to evaluate the effect of treatment with romosozumab for 6 months compared with placebo on the percent changes in bone mineral density (BMD) at the lumbar spine, at the total hip and femoral neck in…
- Trial name
- NCT05067335
- Testing
- Romosozumab
- Where
- 30 sites in China
- Volunteers
- 327 people
- Sponsor
- UCB Biopharma SRL
Femur Neck Fracture
Effect of Teriparatide on Hip Fracture Healing
The purpose of this study is to see whether teriparatide, given for 6 months versus placebo, will improve the healing of hip (femoral neck) fractures that are repaired during surgery using certain types of orthopedic screws.
- Trial name
- NCT01473589
- Testing
- Teriparatide, Calcium supplementation, Vitamin D supplementation
- Where
- 92 sites in United States, Australia and 17 more
- Volunteers
- 122 people
- Sponsor
- Eli Lilly and Company
Myelodysplastic Syndrome (MDS)
A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome
[Tolerability Assessment Part] The purpose is to identify the doses of the oral azacitidine(AZA) formulations and cedazuridine (CED) tablets which achieve a total AUC for AZA comparable to that for AZA injection at 75 mg/m2.
- Trial name
- NCT04608110
- Testing
- ASTX030 (AZA + CED)
- Where
- 10 sites in Japan
- Volunteers
- 59 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Myelodysplastic Syndromes, Anemia
Safety & Pharmacokinetics of Pegolsihematide for Treatment of Anemia Patient With Myelodysplastic Syndromes
The primary objectives of the trial are to assess the safety and pharmacokinetics profile of pegolsihematide for treatment of anemia patient with myelodysplastic syndromes.
- Trial name
- NCT02619097
- Testing
- Pegol-sihematide injection
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Rheumatoid Arthritis With Adequate Bone Quality, Inflammatory Arthritis
PMCF Study on the Safety and Performance of the Zimmer® Maxera™ Acetabular System in Total Hip Arthroplasty
This study is a multicenter, prospective, non-controlled post market clinical follow-up study. The objectives of this study are to confirm the safety and performance of the commercially available Zimmer® Maxera™ Acetabular System…
- Conditions
- Rheumatoid Arthritis With Adequate Bone Quality, Inflammatory Arthritis, Osteoarthritis, Hip, Avascular Necrosis
- Trial name
- NCT03372278
- Where
- 8 sites in Australia, Belgium and 6 more
- Volunteers
- 250 people
- Sponsor
- Zimmer Biomet
Distal Radius Fracture, Scaphoid Fracture
Use of Digital Tomosynthesis for Detection and Case Management of Scaphoid and Distal Radius Fractures: A VolumeRAD Data Collection Study
The study described herein is being conducted to collect clinical data associated with diagnosis and treatment information using the VolumeRAD advanced application.
- Trial name
- NCT03856450
- Testing
- DTS, X-ray, MRI or CT
- Where
- United States
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Myelofibrosis, Myeloproliferative Disorders
A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis
The study consists of two phases: The first portion of the study is a Phase 1 dose escalation study to determine the maximum tolerated dose and the dose limiting toxicities of SB1518 when given as a single agent orally once daily…
- Conditions
- Myelofibrosis, Myeloproliferative Disorders, Polycythemia Vera, Essential Thrombocythemia
- Trial name
- NCT00745550
- Testing
- SB1518
- Where
- 6 sites in United States, Australia
- Volunteers
- 55 people
- Sponsor
- S*BIO
Paroxysmal Nocturnal Hemoglobinuria
Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria
This study is an open-label, single arm, multicenter, roll-over extension study to characterize long-term safety, tolerability and efficacy of iptacopan and to provide access to iptacopan to patients with PNH who have completed…
- Trial name
- NCT04747613
- Testing
- Iptacopan
- Where
- 60 sites in United States, Brazil and 15 more
- Volunteers
- 208 people
- Sponsor
- Novartis Pharmaceuticals